查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1797134

SGLT2 抑制剂市场 - 全球产业规模、份额、趋势、机会和预测，按药物（Jardiance、Farmiga、Inpefa、Invokana 等）、适应症（2 型糖尿病、心血管疾病、其他）、地区和竞争细分，2020 年至 2030 年预测

SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024年全球SGLT2抑制剂市场规模为153.7亿美元，预计2030年将达到214.4亿美元，复合年增长率为5.90%。这类口服降血糖药物因其能够透过促进肾臟排泄葡萄糖来降低血糖水平，同时还具有减肥和降低心血管风险等额外益处，已成为首选的治疗方案。

市场概览
预测期 2026-2030
2024年市场规模 153.7亿美元
2030年市场规模 214.4亿美元
2025-2030 年复合年增长率 5.90%
成长最快的领域 乔迪安斯
最大的市场 北美洲

糖尿病发生率的上升，加上人们对血糖控制不佳相关併发症的认识不断提高，导致越来越多的患者需要有效且耐受性良好的治疗方案。儘管增长前景光明，但高昂的治疗费用、严格的监管要求以及对尿路感染和酮症酸中毒等副作用的担忧等挑战，可能会在一定程度上製约市场扩张。

关键市场驱动因素

医疗保健产业的成长

主要市场挑战

治疗费用高昂

主要市场趋势

糖尿病盛行率上升

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：COVID-19 对全球 SGLT2 抑制剂市场的影响

第五章：全球SGLT2抑制剂市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依药物分类（Jardiance、Farmiga、Inpefa、Invokana 等）
    • 依适应症（2 型糖尿病、心血管疾病、其他）
    • 按地区
    • 按公司分类（2024）
  • 市场地图

第六章：北美SGLT2抑制剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第七章：欧洲SGLT2抑制剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区SGLT2抑制剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第九章：南美洲SGLT2抑制剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲 SGLT2 抑制剂市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购（如有）
  • 产品发布（如有）
  • 最新动态

第十三章：干扰：衝突、流行病与贸易壁垒

第 14 章：全球 SGLT2 抑制剂市场：SWOT 分析

第 15 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 16 章：竞争格局

  • Boehringer Ingelheim International GmbH
  • AstraZeneca
  • Merck & Co., Inc.
  • Janssen Pharmaceuticals, Inc.
  • TheracosBio, LLC
  • Lexicon Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Ltd.

第 17 章：策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 30494

Global SGLT2 Inhibitors Market was valued at USD 15.37 Billion in 2024 and is expected to reach USD 21.44 Billion by 2030 with a CAGR of 5.90%. These oral antidiabetic agents have emerged as a preferred therapeutic option due to their ability to lower blood glucose levels by promoting glucose excretion through the kidneys, while also offering additional benefits such as weight loss and cardiovascular risk reduction.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 15.37 Billion
Market Size 2030USD 21.44 Billion
CAGR 2025-20305.90%
Fastest Growing SegmentJardiance
Largest MarketNorth America

Rising diabetes incidence, coupled with growing awareness of the complications associated with poor glycemic control, has led to an expanding patient pool demanding effective and well-tolerated treatment options. Despite robust growth prospects, challenges such as high treatment costs, stringent regulatory requirements, and concerns about side effects including urinary tract infections and ketoacidosis may constrain market expansion to some extent.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare industry is a significant catalyst driving growth in the SGLT2 inhibitors market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Its largest and most lucrative segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which exceed USD 400 billion. Increasing investments in healthcare infrastructure, advancements in medical technology, and improved access to quality care are collectively enhancing the diagnosis and management of chronic diseases such as type 2 diabetes mellitus (T2DM), which is the primary indication for SGLT2 inhibitors.

Rising healthcare expenditure, particularly in emerging economies, is enabling broader patient access to innovative therapies, including SGLT2 inhibitors. A report from the World Health Organization (WHO) indicates that global health expenditure continued to rise in 2021, the second year of the pandemic, reaching USD 9.8 trillion equivalent to 10.3% of global GDP. This increase was primarily driven by higher government funding and out-of-pocket expenses. Furthermore, the growing emphasis on early diagnosis and comprehensive disease management programs is boosting prescription rates for these novel antidiabetic agents.

Key Market Challenges

High Cost of Therapy

One of the primary challenges facing the global SGLT2 inhibitors market is the high cost of therapy, which can limit patient access and hinder widespread adoption. Despite their proven clinical benefits, SGLT2 inhibitors are often priced at a premium compared to traditional antidiabetic medications, placing a significant financial burden on both patients and healthcare systems, particularly in low- and middle-income countries.

The elevated cost is driven by factors such as complex manufacturing processes, ongoing research and development expenditures, and patent protections that limit the availability of lower-cost generic alternatives. This pricing barrier may result in restricted insurance coverage or reimbursement limitations, thereby reducing affordability for a large segment of the diabetic population.

Key Market Trends

Rising Prevalence of Diabetes

The escalating prevalence of diabetes, particularly type 2 diabetes mellitus (T2DM), is a critical trend shaping the trajectory of the global SGLT2 inhibitors market. According to recent epidemiological data, the number of individuals diagnosed with diabetes continues to rise worldwide, driven by factors such as sedentary lifestyles, urbanization, obesity, and aging populations.

Diabetes statistics highlight the increasing global burden of the disease on individuals, families, and nations. According to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% or 1 in 9 of adults aged 20-79 are living with diabetes, with more than 40% unaware of their condition. This growing patient pool has intensified the demand for effective and innovative therapeutic options, positioning SGLT2 inhibitors as a preferred class of oral antidiabetic agents. Their ability to improve glycemic control, coupled with additional benefits such as cardiovascular and renal protection, has enhanced their clinical appeal and expanded their use.

Key Market Players

  • Boehringer Ingelheim International GmbH
  • AstraZeneca
  • Merck & Co., Inc.
  • Janssen Pharmaceuticals, Inc.
  • TheracosBio, LLC
  • Lexicon Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global SGLT2 Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

SGLT2 Inhibitors Market, By Drug:

  • Jardiance
  • Farmiga
  • Inpefa
  • Invokana
  • Others

SGLT2 Inhibitors Market, By Indication:

  • Type 2 Diabetes
  • Cardiovascular
  • Others

SGLT2 Inhibitors Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global SGLT2 Inhibitors Market.

Available Customizations:

Global SGLT2 Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global SGLT2 Inhibitors Market

5. Global SGLT2 Inhibitors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others)
    • 5.2.2. By Indication (Type 2 Diabetes, Cardiovascular, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America SGLT2 Inhibitors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug
    • 6.2.2. By Indication
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States SGLT2 Inhibitors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug
        • 6.3.1.2.2. By Indication
    • 6.3.2. Mexico SGLT2 Inhibitors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug
        • 6.3.2.2.2. By Indication
    • 6.3.3. Canada SGLT2 Inhibitors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug
        • 6.3.3.2.2. By Indication

7. Europe SGLT2 Inhibitors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug
    • 7.2.2. By Indication
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France SGLT2 Inhibitors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug
        • 7.3.1.2.2. By Indication
    • 7.3.2. Germany SGLT2 Inhibitors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug
        • 7.3.2.2.2. By Indication
    • 7.3.3. United Kingdom SGLT2 Inhibitors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug
        • 7.3.3.2.2. By Indication
    • 7.3.4. Italy SGLT2 Inhibitors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug
        • 7.3.4.2.2. By Indication
    • 7.3.5. Spain SGLT2 Inhibitors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug
        • 7.3.5.2.2. By Indication

8. Asia Pacific SGLT2 Inhibitors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug
    • 8.2.2. By Indication
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China SGLT2 Inhibitors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug
        • 8.3.1.2.2. By Indication
    • 8.3.2. India SGLT2 Inhibitors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug
        • 8.3.2.2.2. By Indication
    • 8.3.3. South Korea SGLT2 Inhibitors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug
        • 8.3.3.2.2. By Indication
    • 8.3.4. Japan SGLT2 Inhibitors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug
        • 8.3.4.2.2. By Indication
    • 8.3.5. Australia SGLT2 Inhibitors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug
        • 8.3.5.2.2. By Indication

9. South America SGLT2 Inhibitors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug
    • 9.2.2. By Indication
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil SGLT2 Inhibitors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug
        • 9.3.1.2.2. By Indication
    • 9.3.2. Argentina SGLT2 Inhibitors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug
        • 9.3.2.2.2. By Indication
    • 9.3.3. Colombia SGLT2 Inhibitors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug
        • 9.3.3.2.2. By Indication

10. Middle East and Africa SGLT2 Inhibitors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug
    • 10.2.2. By Indication
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa SGLT2 Inhibitors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug
        • 10.3.1.2.2. By Indication
    • 10.3.2. Saudi Arabia SGLT2 Inhibitors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug
        • 10.3.2.2.2. By Indication
    • 10.3.3. UAE SGLT2 Inhibitors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug
        • 10.3.3.2.2. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global SGLT2 Inhibitors Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Boehringer Ingelheim International GmbH
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. AstraZeneca
  • 16.3. Merck & Co., Inc.
  • 16.4. Janssen Pharmaceuticals, Inc.
  • 16.5. TheracosBio, LLC
  • 16.6. Lexicon Pharmaceuticals, Inc.
  • 16.7. Eli Lilly and Company
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer